NASDAQ:STOK Stoke Therapeutics (STOK) Stock Price, News & Analysis → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free STOK Stock Alerts $13.50 -0.67 (-4.73%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$12.20▼$14.2550-Day Range$4.12▼$14.1752-Week Range$3.35▼$16.40Volume4.56 million shsAverage Volume2.27 million shsMarket Capitalization$625.05 millionP/E RatioN/ADividend YieldN/APrice Target$19.63 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Stoke Therapeutics alerts: Email Address Stoke Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.78 Rating ScoreUpside/Downside45.4% Upside$19.63 Price TargetShort InterestHealthy12.79% of Float Sold ShortDividend StrengthN/ASustainability-0.59Upright™ Environmental ScoreNews Sentiment0.54Based on 43 Articles This WeekInsider TradingSelling Shares$212,852 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.27) to ($2.69) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.65 out of 5 starsMedical Sector81st out of 939 stocksPharmaceutical Preparations Industry29th out of 443 stocks 4.4 Analyst's Opinion Consensus RatingStoke Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $19.63, Stoke Therapeutics has a forecasted upside of 45.4% from its current price of $13.50.Amount of Analyst CoverageStoke Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted12.79% of the float of Stoke Therapeutics has been sold short.Short Interest Ratio / Days to CoverStoke Therapeutics has a short interest ratio ("days to cover") of 6.3.Change versus previous monthShort interest in Stoke Therapeutics has recently decreased by 5.59%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldStoke Therapeutics does not currently pay a dividend.Dividend GrowthStoke Therapeutics does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreStoke Therapeutics has received a 77.13% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Stoke Therapeutics is -0.59. Previous Next 3.1 News and Social Media Coverage News SentimentStoke Therapeutics has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 43 news articles for Stoke Therapeutics this week, compared to 5 articles on an average week.Search Interest23 people have searched for STOK on MarketBeat in the last 30 days. This is an increase of 475% compared to the previous 30 days.MarketBeat Follows11 people have added Stoke Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 267% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Stoke Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $212,852.00 in company stock.Percentage Held by Insiders12.30% of the stock of Stoke Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Stoke Therapeutics are expected to decrease in the coming year, from ($2.27) to ($2.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Stoke Therapeutics is -5.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Stoke Therapeutics is -5.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioStoke Therapeutics has a P/B Ratio of 2.88. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Stoke Therapeutics Stock (NASDAQ:STOK)Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company is also developing STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is based in Bedford, Massachusetts.Read More STOK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart STOK Stock News HeadlinesMarch 20, 2024 | insidertrades.comInsider Selling: Stoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Sells 2,349 Shares of StockMarch 29, 2024 | americanbankingnews.comAnalysts Issue Forecasts for Stoke Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:STOK)March 29, 2024 | DTI (Ad)Warning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…March 29, 2024 | americanbankingnews.comStoke Therapeutics, Inc. (NASDAQ:STOK) to Post Q1 2024 Earnings of ($0.61) Per Share, Wedbush ForecastsMarch 28, 2024 | americanbankingnews.comStoke Therapeutics (NASDAQ:STOK) Sets New 12-Month High on Analyst UpgradeMarch 27, 2024 | businesswire.comStoke Therapeutics Announces Pricing of Upsized $125 Million Public OfferingMarch 27, 2024 | markets.businessinsider.comStoke Therapeutics’ STK-001 Shows Promise: Buy Rating Affirmed Amid Positive Clinical and Financial OutlookMarch 27, 2024 | marketwatch.comStoke Therapeutics Shares Extend Gains to 52-Week High, Plans for $75M OfferingMarch 29, 2024 | Crypto 101 Media (Ad)Altcoin FRENZY Alert…Bitcoin recently crossed the highest price in its 15-year history… Less than 2 years after one of the most vicious crypto market meltdowns we've ever seen! Bitcoin's BOOM also sent shockwaves through the altcoin market, with select coins seeing HUGE moves in a matter of days… Like Fetch.ai, that gained over 350% in just the last 30 days… March 27, 2024 | bizjournals.comStoke Therapeutics plans $75M public offering on heels of Dravet trial resultsMarch 27, 2024 | msn.comWhat's Going On With Stoke Therapeutics Stock Tuesday?March 27, 2024 | msn.comShares in Bedford-based Stoke Therapeutics surge after encouraging results in studies of epilepsy medicineMarch 27, 2024 | americanbankingnews.comStoke Therapeutics (NASDAQ:STOK) Given New $17.00 Price Target at WedbushMarch 27, 2024 | americanbankingnews.comStoke Therapeutics (NASDAQ:STOK) Given New $22.00 Price Target at Needham & Company LLCMarch 27, 2024 | americanbankingnews.comStoke Therapeutics (NASDAQ:STOK) Receives "Buy" Rating from HC WainwrightMarch 27, 2024 | americanbankingnews.comStoke Therapeutics (NASDAQ:STOK) Given New $13.00 Price Target at JPMorgan Chase & Co.March 27, 2024 | americanbankingnews.comStoke Therapeutics (NASDAQ:STOK) Price Target Raised to $21.00 at Canaccord Genuity GroupMarch 27, 2024 | americanbankingnews.comStoke Therapeutics (NASDAQ:STOK) Upgraded to "Outperform" at TD CowenMarch 27, 2024 | americanbankingnews.comStoke Therapeutics (NASDAQ:STOK) Shares Gap Up Following Analyst UpgradeMarch 26, 2024 | businesswire.comStoke Therapeutics Announces Proposed Public OfferingMarch 26, 2024 | msn.comTD Cowen ups Stoke to buy on updated data for epilepsy drugMarch 26, 2024 | msn.comStoke stock rockets 73% on updated epilepsy drug dataMarch 26, 2024 | finance.yahoo.comStoke Therapeutics' Anti-Epilepsy Drug Candidate Shows Substantial, Sustained Reductions In Seizure Frequency In Pretreated PatientsMarch 26, 2024 | investorplace.comWhy Is Stoke Therapeutics (STOK) Stock Up 99% Today?March 25, 2024 | investorplace.comSTOK Stock Earnings: Stoke Therapeutics Beats EPS, Misses Revenue for Q4 2023March 25, 2024 | msn.comStoke stock soars 70% post-market on epilepsy drug dataMarch 25, 2024 | businesswire.comStoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet SyndromeSee More Headlines Receive STOK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Stoke Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/07/2023Today3/28/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:STOK CUSIPN/A CIK1623526 Webwww.stoketherapeutics.com Phone(781) 430-8200FaxN/AEmployees117Year FoundedN/APrice Target and Rating Average Stock Price Target$19.63 High Stock Price Target$35.00 Low Stock Price Target$12.00 Potential Upside/Downside+45.4%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($2.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-101,070,000.00 Net MarginsN/A Pretax Margin-1,192.47% Return on Equity-56.86% Return on Assets-41.59% Debt Debt-to-Equity RatioN/A Current Ratio6.99 Quick Ratio9.13 Sales & Book Value Annual Sales$8.78 million Price / Sales71.19 Cash FlowN/A Price / Cash FlowN/A Book Value$4.69 per share Price / Book2.88Miscellaneous Outstanding Shares46,300,000Free Float39,162,000Market Cap$625.05 million OptionableOptionable Beta0.68 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Edward M. Kaye M.D. (Age 75)Ph.D., CEO & Director Comp: $931.21kDr. Adrian R. Krainer Ph.D. (Age 65)Co-Founder & Independent Director Comp: $44kMr. Stephen J. Tulipano CPA (Age 65)MBA, Chief Financial Officer Comp: $619.09kDr. Barry S. Ticho FACC (Age 63)M.D., Ph.D., Chief Medical Officer Comp: $688.83kMs. Isabel Aznarez Ph.D. (Age 51)Co-Founder & Group VP of Discovery Research Dr. Huw M. Nash Ph.D. (Age 57)COO & Chief Business Officer Comp: $429.67kMr. Eric RojasHead of Investor RelationsMr. Jonathan Allan J.D. (Age 34)Corporate Secretary & General Counsel Ms. Dawn Kalmar (Age 46)Chief Communications Officer Ms. Joan WoodChief Human Resources OfficerMore ExecutivesKey CompetitorsLarimar TherapeuticsNASDAQ:LRMRAltimmuneNASDAQ:ALTEntrada TherapeuticsNASDAQ:TRDANeoleukin TherapeuticsNASDAQ:NLTXDianthus TherapeuticsNASDAQ:DNTHView All CompetitorsInsiders & InstitutionsEdward M Md KayeSold 11,150 sharesTotal: $68,015.00 ($6.10/share)Stephen J TulipanoSold 4,116 sharesTotal: $25,107.60 ($6.10/share)Jonathan AllanSold 2,349 sharesTotal: $14,328.90 ($6.10/share)Vanguard Group Inc.Bought 17,814 shares on 3/11/2024Ownership: 3.692%GSA Capital Partners LLPSold 245,962 shares on 2/16/2024Ownership: 0.229%View All Insider TransactionsView All Institutional Transactions STOK Stock Analysis - Frequently Asked Questions Should I buy or sell Stoke Therapeutics stock right now? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stoke Therapeutics in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" STOK shares. View STOK analyst ratings or view top-rated stocks. What is Stoke Therapeutics' stock price target for 2024? 9 brokers have issued 12 month target prices for Stoke Therapeutics' shares. Their STOK share price targets range from $12.00 to $35.00. On average, they anticipate the company's share price to reach $19.63 in the next twelve months. This suggests a possible upside of 45.4% from the stock's current price. View analysts price targets for STOK or view top-rated stocks among Wall Street analysts. How have STOK shares performed in 2024? Stoke Therapeutics' stock was trading at $5.26 at the beginning of 2024. Since then, STOK shares have increased by 156.7% and is now trading at $13.50. View the best growth stocks for 2024 here. When is Stoke Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our STOK earnings forecast. How were Stoke Therapeutics' earnings last quarter? Stoke Therapeutics, Inc. (NASDAQ:STOK) released its earnings results on Monday, August, 7th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.63) by $0.06. The company earned ($2.48) million during the quarter, compared to analysts' expectations of $4 million. What ETFs hold Stoke Therapeutics' stock? ETFs with the largest weight of Stoke Therapeutics (NASDAQ:STOK) stock in their portfolio include Morningstar US Small Growth (MSGR) and Simplify Propel Opportunities ETF (SURI).Global X Genomics & Biotechnology ETF (GNOM). What other stocks do shareholders of Stoke Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Stoke Therapeutics investors own include Gossamer Bio (GOSS), Editas Medicine (EDIT), Alector (ALEC), LogicBio Therapeutics (LOGC), NVIDIA (NVDA), Precision BioSciences (DTIL), Kaleido Biosciences (KLDO), Homology Medicines (FIXX), Marvell Technology (MRVL) and Invitae (NVTA). When did Stoke Therapeutics IPO? Stoke Therapeutics (STOK) raised $100 million in an initial public offering on Wednesday, June 19th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity was co-manager. Who are Stoke Therapeutics' major shareholders? Stoke Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include RTW Investments LP (9.25%), Vanguard Group Inc. (3.69%), Vanguard Group Inc. (3.69%), Goldman Sachs Group Inc. (3.12%), Granahan Investment Management LLC (2.55%) and Northern Trust Corp (0.58%). Insiders that own company stock include Barry Ticho, Edward M Md Kaye, Huw M Nash, Jonathan Allan and Stephen J Tulipano. View institutional ownership trends. How do I buy shares of Stoke Therapeutics? Shares of STOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:STOK) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingFed launches fourth dollar overhaulStansberry ResearchThe 3rd Revolution in WarfareWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Stoke Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.